Moctezuma-Velázquez Carlos, Abraldes Juan G
Gastroenterology (Liver Unit), University of Alberta, Canada.
Rev Esp Enferm Dig. 2023 Mar;115(3):107-109. doi: 10.17235/reed.2022.9281/2022.
In this editorial, we briefly mention the studies that support the use of statins to change the natural history of liver cirrhosis, alongside potential biases and flaws that need to be considered when analyzing data. The key message that we want to communicate is that even if current evidence is somehow compelling, it is limited, mostly from observational studies, and in general not enough to formally recommend the prescription of statins in patients with cirrhosis as disease-modifying agents. Finally, we also mention some important facts about the safety of statins in the context of patients with underlying liver disease.
在这篇社论中，我们简要提及了支持使用他汀类药物来改变肝硬化自然病程的研究，以及分析数据时需要考虑的潜在偏倚和缺陷。我们想要传达的关键信息是，即使当前证据在某种程度上具有说服力，但它是有限的，大多来自观察性研究，总体上不足以正式推荐将他汀类药物作为疾病改善药物用于肝硬化患者的处方。最后，我们还提到了在患有基础肝病的患者背景下他汀类药物安全性的一些重要事实。
